<DOC>
	<DOCNO>NCT00203151</DOCNO>
	<brief_summary>It think Edratide may able reduce symptom SLE .</brief_summary>
	<brief_title>A Study Evaluate Tolerability , Safety Effectiveness Edratide Treatment Lupus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>1 . Willing able give write informed consent 2 . Between age 18 65 year ( inclusive ) 3 . Fulfilled least 4 ACR classification criterion 4 . SLE patient moderate , active disease 5 . Subjects stable dose SLE medication least 4 week randomization . 6 . Women childbearing potential must practice medically acceptable method contraception.. 7 . Must understand requirement study agree comply study protocol . 1 . Any condition investigator feel may interfere participation study . 2 . Subjects history chronic infection 3 . Subjects history immunodeficiency syndrome malignancy , 4 . Subjects receive investigational medication ( include DHEA ) within 3 month prior randomization , 5 . Subjects treat cytotoxic agent 3 month prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>